LXX Lexaria Bioscience Corp

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on March 28, 2018.

“Lexaria has become a leading innovator of cannabinoid delivery systems,” said Frank Lane, President of CFN Media. “The company’s DehydraTECH™ technology helps improve the bioavailability, absorption and taste of cannabinoids by encapsulating them in a lipid layer. We’re excited to be working with the company again as they expand their IP portfolio and commercialize these technologies.”

”We are pleased to be working again with CFN Media with their expertise in conveying the Lexaria story to as broad of a mainstream and cannabis-focused audience as possible,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “2018 is going to be a breakout year for Lexaria and CFN Media will ensure that everyone is reliably informed.”

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to Lexaria Bioscience Corp. while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading agency and financial media network dedicated to the worldwide cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Private and public marijuana companies in the US and Canada rely on CFN Media to succeed in the capital markets.

About Lexaria Biosciences Inc.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.

Contact: Frank Lane 206-369-7050 Flane@cannabisfn.com